Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Bacillus anthracis strain V770-NP1-R antigens · Biothrax

Vaccine (Recombinant protein vaccine) · Immune activation, directed at Bacillus anthracis protective antigen · developed by Emergent BioDefense Operations Lansing LLC

Approved FDA, Nov 1998

EBS Developer

3 Registered trials

What is Bacillus anthracis strain V770-NP1-R antigens?

Bacillus anthracis strain V770-NP1-R antigens, marketed as BioThrax and CYFENDUS, is an adsorbed anthrax vaccine given intramuscularly. It is studied in healthy volunteers and in anthrax, including cutaneous, gastrointestinal and inhalation forms.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Biothrax, BioThrax, CYFENDUS
Drug type: Vaccine (Recombinant protein vaccine)
Targets: Bacillus anthracis protective antigen (antigen)
Mechanism: Immune activation, directed at Bacillus anthracis protective antigen
Therapy area: Infectious disease
Developer: Emergent BioDefense Operations Lansing LLC (EBS)
Also in trials of: ALT
FDA status: Approved as Biothrax (November 12, 1998), BLA103821
UNII: 873OI62848

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03877926	Phase 3	Anthrax	Completed	EBS
NCT03352466	Phase 1	Healthy Volunteers	Completed	ALT
NCT07268612	N/A	Anthrax	Not yet recruiting	EBS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AnthraxHealthy Volunteers

More from Emergent BioDefense Operations Lansing LLC

AIGIV FDA approved Brincidofovir FDA approved smallpox vaccine live, New York City Board of Health vaccinia strain FDA approved Vaccinia Immune Globulin FDA approved Ad4-EnvC150 Phase 1 Ad4-H5-Vtn Phase 1 Ad4-mgag Phase 1 Ad4-PA-1 Phase 1 Ad4-PA-GPI-1 Phase 1 AIDSVAX B/E Phase 1 AV7909 Phase 3 Botulinum Antitoxin Heptavalent Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the EBS page.

Follow EBS, the company behind Bacillus anthracis strain V770-NP1-R antigens

See EBS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EBS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z